A 12-year retrospective clinical study of patients who received peptide receptor radionuclide therapy for malignant neuroendocrine tumors demonstrates the long-term effectiveness of this treatment, which also allows patients to maintain a high quality of life.
Click here for original story, Twelve-year follow-up after peptide receptor radionuclide therapy
Source: ScienceDaily